pantoprazole has been researched along with Chronic Kidney Diseases in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, S | 1 |
| Zhao, J | 1 |
| Chen, X | 1 |
| Xu, S | 1 |
| Yang, X | 1 |
| Zhang, Y | 1 |
| Ma, Z | 1 |
| Jiang, H | 1 |
| Zhou, H | 1 |
1 other study available for pantoprazole and Chronic Kidney Diseases
| Article | Year |
|---|---|
Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation.
Topics: Animals; Cytochrome P-450 CYP2E1; Indican; Lansoprazole; Mice; Omeprazole; Pantoprazole; Proteolysis | 2022 |